State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Med Oncol. 2012 Jun;29(2):1127-33. doi: 10.1007/s12032-011-9902-3. Epub 2011 Mar 10.
The aim of our study is to investigate the clinical characteristics and prognostic factors in Chinese Hodgkin's lymphoma patients. It is known that clinical characteristics and epidemiology of Hodgkin's lymphoma in China are different from Western countries. In total, 137 consecutive, previously untreated patients with Hodgkin's lymphoma at Sun Yat-Sen University Cancer Center were enrolled. Among these patients, 92 were male and 45 were female, with a median age of 28 (range: 2-76) years. The bimodal age curve of classical Hodgkin's lymphoma analyzed from our patients was not obvious as the Western population, showing an early peak in 25 years and a second peak in 45 years. Most of the patients (41.6%) were classified as nodular sclerosis classic Hodgkin's lymphoma. Results showed that the 5-year overall survival, event-free survival, and disease-free survival rates were 97.7, 85.0, and 94.0%, respectively. Lymphopenia at diagnosis was related to poorer overall survival (P = 0.015) and event-free survival (P < 0.001) in all-stage Hodgkin's lymphoma patients. Multivariate analysis showed that lymphopenia as an independent unfavorable prognostic factor influenced event-free survival (P = 0.015). The international prognostic score ≥ 5 was also the only independent prognostic factor of disease-free survival in advanced-stage patients (P = 0.046). Our findings demonstrated that some clinical characteristics of Hodgkin's lymphoma in China were different from those in the Western countries. Lymphopenia was an effective prognostic predictor in both early stage and advanced stage.
本研究旨在探讨中国霍奇金淋巴瘤患者的临床特征和预后因素。已知中国霍奇金淋巴瘤的临床特征和流行病学与西方国家不同。本研究共纳入中山大学肿瘤防治中心 137 例初治、未经治疗的霍奇金淋巴瘤患者,其中男 92 例,女 45 例,中位年龄 28 岁(范围:2-76 岁)。对本研究患者进行分析后发现,经典霍奇金淋巴瘤的双峰年龄曲线不明显,与西方人群不同,表现为 25 岁和 45 岁的两个高峰。大多数患者(41.6%)为结节性硬化型经典霍奇金淋巴瘤。结果显示,所有分期患者的 5 年总生存率、无事件生存率和无病生存率分别为 97.7%、85.0%和 94.0%。所有分期的霍奇金淋巴瘤患者中,诊断时的淋巴细胞减少与总生存率(P = 0.015)和无事件生存率(P < 0.001)较差相关。多因素分析显示,淋巴细胞减少作为独立的不良预后因素,影响无事件生存率(P = 0.015)。国际预后评分≥5 也是晚期患者无病生存率的唯一独立预后因素(P = 0.046)。本研究结果表明,中国霍奇金淋巴瘤的某些临床特征与西方国家不同。淋巴细胞减少是早期和晚期患者的有效预后预测因素。